Revenue (Quarterly)

Revenue: The sum of all revenue fields included for a company's operating activities.

Halozyme Therapeutics, Inc. (HALO) had Revenue of $354.26M for the most recently reported fiscal quarter, ending 2025-09-30.

Quarterly Annual

Figures for fiscal quarter ending 2025-09-30

Income Statement Financials
Revenue	$354.26M
Net Income	$175.22M
Cost of Goods Sold	$55.24M
Gross Profit	$299.02M
Operating Expenses	$136.34M
Operating Income	$217.92M
Non-Operating Income/Expense	$1.04M
Pre-Tax Income	$218.96M
Normalized Pre-Tax Income	$218.96M
Income after Taxes	$175.22M
Income from Continuous Operations	$175.22M
Consolidated Net Income/Loss	$175.22M
Normalized Income after Taxes	$175.22M
EBIT	$217.92M
EBITDA	$239.84M
Weighted-Average Shares Outstanding (Basic)	117.22M
Weighted-Average Shares Outstanding (Diluted)	122.33M
Earnings per Share (EPS) (Basic)	$1.49
Earnings per Share (EPS) (Diluted)	$1.43
Balance Sheet Financials
Current Assets	$1.33B
Property, Plant, and Equipment	$71.42M
Long-Term Assets	$892.48M
Total Assets	$2.22B
Current Liabilities	$837.23M
Long-Term Debt	$800.07M
Long-Term Liabilities	$880.09M
Total Liabilities	$1.72B
Common Equity	$503.92M
Tangible Shareholders Equity	$-261.45M
Shareholders Equity	$503.92M
Common Shares Outstanding	117.52M
Cash Flow Statement Financials
Cash Flow from Operating Activities	$432.53M
Cash Flow from Investing Activities	$195.97M
Cash Flow from Financial Activities	$-324.69M
Beginning Cash	$115.85M
End Cash	$419.67M
Increase/Decrease in Cash	$303.81M
Stock-Based Compensation	$34.99M
Common Stock Dividends Paid	--
Preferred Stock Dividends Paid	--
Fundamental Metrics & Ratios
Current Ratio	1.59
Non-Performing Assets / Total Loans	--
Loan Loss Reserves / Non-Performing Loans	--
Debt to Capital Ratio	0.61
Debt to Equity Ratio	3.00
Gross Margin	84.41%
Operating Margin	61.51%
EBIT Margin	61.51%
EBITDA Margin	--
Pre-Tax Profit Margin	61.81%
Profit Margin	49.46%
Free Cash Flow	$875.86M
Loss Ratio	--
Expense Ratio	--
Combined Ratio	--
Asset Turnover	0.16
Inventory Turnover	0.30
Receiveable Turnover	1.02
Days Sales in Receivables	87.91
Return on Equity	34.77%
Return on Tangible Equity	-67.02%
Return on Assets	7.89%
Return on Investments	13.44%
Book Value Per Share	$4.29
Free Cash Flow per Share	$7.16
Operating Cash Flow per Share	$3.54

Data from Zacks Investment Research, Inc.